Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04816214
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04786964
- Locations
- 🇹🇭
Research Site, Chiang Mai, Thailand
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 200
- Registration Number
- NCT04768075
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 606
- Registration Number
- NCT04762459
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, China
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Shirish Gadgeel
- Registration Number
- NCT04754815
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Taizhou Hanzhong biomedical co. LTD
- Target Recruit Count
- 700
- Registration Number
- NCT04750083
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Liaoning Cancer Hospital & Insititute, Shenyang, Liaoning, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 296
- Registration Number
- NCT04736823
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT04736173
- Locations
- 🇺🇸
City of Hope-Duarte, Duarte, California, United States
🇺🇸City of Hope - Huntington Beach (Including Long Beach Elm), Huntington Beach, California, United States
🇺🇸City Of Hope, Irvine, California, United States
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 456
- Registration Number
- NCT04717375
- Locations
- 🇺🇸
Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte, California, United States
🇺🇸Smilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven, Connecticut, United States
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 201
- Registration Number
- NCT04716933
- Locations
- 🇨🇳
Fujian Provincial Cancer Hospital ( Site 0102), Fuzhou, Fujian, China
🇨🇳Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110), Urumuqi, Xinjiang, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University ( Site 0124), Wen Zhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.